dMed Biopharmaceutical

Founded in 2016, dMed is a full-service Clinical Contract Research Organization (CRO), and has grown to nearly 700 professional staff covering more than 31 cities in China and three U.S. offices. In an era of unparalleled pharmaceutical innovation, dMed aspires to be a next-generation clinical development partner, empowering customers to deliver innovative solutions to patients worldwide, especially in the two largest healthcare markets, the U.S. and China. dMed's U.S. presence includes Target Health, a full service technology driven CRO with expertise in digital capabilities and regulatory affairs.